Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Model-informed target product profiles of long acting-injectables for use as seasonal malaria prevention

Lydia Burgert, Theresa Reiker, Monica Golumbeanu, Jörg J. Möhrle, View ORCID ProfileMelissa A. Penny
doi: https://doi.org/10.1101/2021.07.05.21250483
Lydia Burgert
1Swiss Tropical and Public Health Institute, Basel, Switzerland
2University of Basel, Basel, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Theresa Reiker
1Swiss Tropical and Public Health Institute, Basel, Switzerland
2University of Basel, Basel, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Monica Golumbeanu
1Swiss Tropical and Public Health Institute, Basel, Switzerland
2University of Basel, Basel, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jörg J. Möhrle
1Swiss Tropical and Public Health Institute, Basel, Switzerland
2University of Basel, Basel, Switzerland
3Medicines for Malaria Venture, Geneva, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Melissa A. Penny
1Swiss Tropical and Public Health Institute, Basel, Switzerland
2University of Basel, Basel, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Melissa A. Penny
  • For correspondence: melissa.penny@unibas.ch
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

1. Abstract

Seasonal malaria chemoprevention (SMC) has proven highly efficacious in reducing malaria incidence. However, the continued success of SMC is threatened by the spread of resistance against one of its main preventive ingredients, Sulfadoxine-Pyrimethamine(SP), operational challenges in delivery, and incomplete adherence to the regimens. Via a simulation study with an individual-based model of malaria dynamics, we provide quantitative evidence to assess long-acting injectables (LAIs) as potential alternatives to SMC. We explored the predicted impact of a range of novel preventive LAIs as a seasonal prevention tool in children aged three months to five years old during late-stage clinical trials and at implementation. LAIs were co-administered with a blood-stage clearing drug once at the beginning of the transmission season. We found the establishment of non-inferiority of LAIs to standard 3 or 4 rounds of SMC with SP-amodiaquine was challenging in clinical trial stages due to high intervention deployment coverage. However, our analysis of implementation settings where the achievable SMC coverage was much lower, LAIs with fewer visits per season are potential suitable replacements to SMC. Suitability as a replacement with higher impact is possible if the duration of protection of LAIs covered the duration of the transmission season. Furthermore, optimizing LAIs coverage and protective efficacy half-life via simulation analysis in settings with an SMC coverage of 60% revealed important trade-offs between protective efficacy decay and deployment coverage. Our analysis additionally highlights that for seasonal deployment for LAIs, it will be necessary to investigate the protective efficacy decay as early as possible during clinical development to ensure a well-informed candidate selection process.

Competing Interest Statement

J.J.M. is employed by the Medicines for Malaria Venture. All other authors declare no competing interests.

Clinical Trial

Not applicable

Funding Statement

The work was funded by the Swiss National Science Foundation through SNSF Professorship of MAP (PP00P3_170702).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

As this is a simulation study no IRB or ethics committee approvals are required

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • We updated funding and role of funders

Data Availability

Simulated results are available, no clinical or preclinical data was used in this study

  • List of abbreviations

    SMC
    Seasonal malaria chemoprevention
    LAI
    Long acting injectable
    TPP
    Target product profile
    mAB
    Monoclonal antibody
    SP+AQ
    Sulfadoxine-Pyrimethamine+Amodiaquine
    GP
    Gaussian process
  • Copyright 
    The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
    Back to top
    PreviousNext
    Posted July 08, 2021.
    Download PDF
    Data/Code
    Email

    Thank you for your interest in spreading the word about medRxiv.

    NOTE: Your email address is requested solely to identify you as the sender of this article.

    Enter multiple addresses on separate lines or separate them with commas.
    Model-informed target product profiles of long acting-injectables for use as seasonal malaria prevention
    (Your Name) has forwarded a page to you from medRxiv
    (Your Name) thought you would like to see this page from the medRxiv website.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Share
    Model-informed target product profiles of long acting-injectables for use as seasonal malaria prevention
    Lydia Burgert, Theresa Reiker, Monica Golumbeanu, Jörg J. Möhrle, Melissa A. Penny
    medRxiv 2021.07.05.21250483; doi: https://doi.org/10.1101/2021.07.05.21250483
    Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
    Citation Tools
    Model-informed target product profiles of long acting-injectables for use as seasonal malaria prevention
    Lydia Burgert, Theresa Reiker, Monica Golumbeanu, Jörg J. Möhrle, Melissa A. Penny
    medRxiv 2021.07.05.21250483; doi: https://doi.org/10.1101/2021.07.05.21250483

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Subject Area

    • Epidemiology
    Subject Areas
    All Articles
    • Addiction Medicine (280)
    • Allergy and Immunology (579)
    • Anesthesia (141)
    • Cardiovascular Medicine (1960)
    • Dentistry and Oral Medicine (253)
    • Dermatology (186)
    • Emergency Medicine (334)
    • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (702)
    • Epidemiology (11120)
    • Forensic Medicine (8)
    • Gastroenterology (629)
    • Genetic and Genomic Medicine (3195)
    • Geriatric Medicine (310)
    • Health Economics (566)
    • Health Informatics (2048)
    • Health Policy (864)
    • Health Systems and Quality Improvement (789)
    • Hematology (310)
    • HIV/AIDS (685)
    • Infectious Diseases (except HIV/AIDS) (12742)
    • Intensive Care and Critical Care Medicine (708)
    • Medical Education (318)
    • Medical Ethics (92)
    • Nephrology (337)
    • Neurology (3000)
    • Nursing (165)
    • Nutrition (465)
    • Obstetrics and Gynecology (589)
    • Occupational and Environmental Health (614)
    • Oncology (1561)
    • Ophthalmology (478)
    • Orthopedics (185)
    • Otolaryngology (266)
    • Pain Medicine (202)
    • Palliative Medicine (57)
    • Pathology (403)
    • Pediatrics (914)
    • Pharmacology and Therapeutics (384)
    • Primary Care Research (355)
    • Psychiatry and Clinical Psychology (2795)
    • Public and Global Health (5612)
    • Radiology and Imaging (1100)
    • Rehabilitation Medicine and Physical Therapy (636)
    • Respiratory Medicine (764)
    • Rheumatology (341)
    • Sexual and Reproductive Health (315)
    • Sports Medicine (289)
    • Surgery (347)
    • Toxicology (48)
    • Transplantation (159)
    • Urology (133)